Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis.

Cancer Med · 2020 · PMC7571828 · PMID 32869544

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

approached significanceno p-value reported

Importantly, the difference in OS between PD‐L1 inhibitors and PD‐1 inhibitors approached significance (HR = 0.99 and 0.77, respectively, p for the subgroup difference 0.08), suggesting possible improved efficacy of PD‐1 inhibitors in gastric or GEJ adenocarcinoma, though this difference was not statistically significant.

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.